In The News Posted August 5, 2021 Share Posted August 5, 2021 HUDDINGE, Aug. 5, 2021 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) today announces that an e-poster entitled "Phase 1 study of the novel prodrug MIV-818 in patients with hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (iCCA) or liver metastases (LM)" will be...View the full article Link to comment Share on other sites More sharing options...
Recommended Posts
Create an account or sign in to comment
You need to be a member in order to leave a comment
Create an account
Sign up for a new account in our community. It's easy!
Register a new accountSign in
Already have an account? Sign in here.
Sign In Now